What oral dose of promethazine suspension (6.25 mg per 5 mL) should I prescribe for a 27‑year‑old patient with Crohn’s disease who needs treatment for nausea?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 8, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Promethazine Oral Suspension Dosing for Nausea in a 27-Year-Old with Crohn's Disease

For nausea treatment in this adult patient, prescribe promethazine 12.5–25 mg (10–20 mL of the 6.25 mg/5 mL suspension) every 4–6 hours as needed, with a typical prescription of 120–240 mL to provide 6–12 doses for acute symptom management. 1, 2

Standard Dosing Parameters

The FDA-approved dosing for nausea and vomiting in adults is 25 mg, which can be repeated every 4–6 hours as necessary. 2 However, lower doses of 12.5 mg are equally effective for antiemetic purposes while causing significantly less sedation, making this the preferred starting dose in most clinical scenarios. 3

Practical Prescription Calculation

With your 6.25 mg/5 mL suspension:

  • 12.5 mg dose = 10 mL (preferred starting dose)
  • 25 mg dose = 20 mL (standard FDA dose)

A reasonable prescription would be 120–240 mL, which provides:

  • At 12.5 mg per dose: 12–24 doses
  • At 25 mg per dose: 6–12 doses

This quantity allows for 3–6 days of treatment at the maximum frequency (every 4 hours), which is appropriate for acute nausea management. 2

Evidence Supporting Lower-Dose Efficacy

Research demonstrates that 6.25 mg IV promethazine provides equivalent antiemetic efficacy to ondansetron 4 mg, with 74% of patients experiencing relief at one hour. 4 Similarly, 6.25 mg IV was as effective as 12.5 mg IV in controlling postoperative nausea, with 97% of patients reporting total relief, while producing significantly less sedation. 5

In elderly patients, 6.25 mg showed no difference in time to relief compared to 12.5 mg, but had significantly fewer adverse drug reactions (P = 0.048). 6 While these studies used IV administration, the principle of dose-response applies to oral therapy, supporting the use of lower doses when clinically appropriate.

Clinical Considerations for This Patient

Crohn's Disease Context

The American Gastroenterological Association guidelines specifically list promethazine 12.5–25 mg by mouth every 4–6 hours as an abortive therapy for nausea in gastrointestinal conditions, including cyclic vomiting syndrome. 1 This dosing is directly applicable to your patient with Crohn's disease experiencing URI-related nausea.

Duration of Action

Promethazine has an onset of action within 20 minutes after oral administration and a duration of 4–6 hours, though effects may persist up to 12 hours. 7, 3 The plasma half-life is 9–16 hours. 7

Safety Warnings and Monitoring

Key adverse effects to counsel the patient about include:

  • CNS depression and significant sedation, particularly problematic if combined with opioids or other sedatives 1, 3
  • Anticholinergic effects (dry mouth, urinary retention, constipation) 1
  • Extrapyramidal symptoms ranging from restlessness to dystonia, though rare with short-term use 1, 3

Advise the patient to:

  • Avoid driving or operating machinery until they know how the medication affects them
  • Not combine with alcohol or other CNS depressants
  • Use the lowest effective dose (start with 12.5 mg/10 mL rather than 25 mg/20 mL)
  • Seek immediate care if they develop muscle stiffness, tremors, or abnormal movements 3

Prescribing Recommendation

Write the prescription as:

  • Promethazine HCl 6.25 mg/5 mL oral solution
  • Dispense: 180 mL (a middle-ground quantity)
  • Sig: Take 10–20 mL (12.5–25 mg) by mouth every 4–6 hours as needed for nausea
  • Instruct to start with 10 mL (12.5 mg) and increase to 20 mL (25 mg) only if inadequate relief 3, 4

This approach prioritizes efficacy while minimizing sedation and other adverse effects, which is particularly important in a young adult who likely needs to maintain daily function despite his URI symptoms. 4, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Promethazine Prescription Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

A comparison of two differing doses of promethazine for the treatment of postoperative nausea and vomiting.

Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses, 2015

Guideline

Mechanism of Action and Clinical Applications of Promethazine

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.